目的 研究左卡尼汀口服溶液聯(lián)合阿魏酸哌嗪片對糖尿病腎病患者的治療效果。方法 選擇2015年6月—2018年6月榆林市第二醫(yī)院收治的100例糖尿病腎病患者，隨機(jī)分為兩組。對照組口服阿魏酸哌嗪片治療，2片/次，3次/d。觀察組聯(lián)合口服左卡尼汀口服溶液，10 mL/次，2次/d。兩組患者均治療4周。觀察兩組患者的臨床療效，同時比較兩組治療前后的血清炎癥因子、24 h尿蛋白定量、尿白蛋白排泄率、血肌酐、血尿素氮以及肌酐清除率。結(jié)果 治療后，觀察組的總有效率為86.00%，明顯高于對照組的70.00%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組治療后的血清白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、C反應(yīng)蛋白（CRP）水平均明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組明顯低于對照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組治療后的24 h尿蛋白定量、尿白蛋白排泄率以及肌酐清除率均明顯降低，血肌酐、血尿素氮水平升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組腎功能指標(biāo)明顯優(yōu)于對照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 左卡尼汀口服溶液聯(lián)合阿魏酸哌嗪片有助于提高糖尿病腎病患者的治療效果，改善患者的微炎癥狀態(tài)和腎功能，值得推廣應(yīng)用。

Objective To investigate the effect of Levocarnitine Oral Solution combined with Piperazine Ferulate Tablets on patients with diabetic nephropathy. Methods Selected 100 cases of patients with diabetic nephropathy who were treated in Yulin Second Hospital from June 2015 to June 2018 were divided into two groups randomly. The control group was treated with Piperazine Ferulate Tablets, 2 tablets/time, three times daily. Patients in the observation group were po administered with Levocarnitine Oral Solution, 10 mL/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy in two groups were observed, and the serum inflammatory factors, 24 h urinary protein, urinary albumin excretion rate, serum creatinine, blood urea nitrogen, and creatinine clearance rate before and after treatment were compared. Results After treatment, the effective rate of the observation group was 86.00%, which was significantly higher than 70.00% in the control group, and there were differences between two groups (P<0.05). After treatment, the serum levels of IL-6, TNF-α, and CRP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the indexes in observation group were significantly lower than those in the control group, with significant differences between two groups (P<0.05). After treatment, the 24 h urine protein quantitative, urinary albumin excretion rate, and creatinine clearance rate in two groups were significantly decreased, but the serum creatinine and blood urea nitrogen were incresead, and the difference was statistically significant in the same group (P<0.05). And the renal indexes in the observation group were obviously better than those in the control group (P<0.05). Conclusion Levocarnitine Oral Solution combined with Piperazine Ferulate Tablets can help improve the therapeutic effect of diabetic nephropathy patients, and improve their micro inflammatory state and renal function, which has a certain clinical application value.